BR112015028054A2 - método para obter uma suspensão estabilizada de glóbulos vermelhos e suspensão estabilizada - Google Patents
método para obter uma suspensão estabilizada de glóbulos vermelhos e suspensão estabilizadaInfo
- Publication number
- BR112015028054A2 BR112015028054A2 BR112015028054A BR112015028054A BR112015028054A2 BR 112015028054 A2 BR112015028054 A2 BR 112015028054A2 BR 112015028054 A BR112015028054 A BR 112015028054A BR 112015028054 A BR112015028054 A BR 112015028054A BR 112015028054 A2 BR112015028054 A2 BR 112015028054A2
- Authority
- BR
- Brazil
- Prior art keywords
- suspension
- less
- stabilized suspension
- solution
- blood cells
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title abstract 9
- 210000003743 erythrocyte Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000243 solution Substances 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000011534 incubation Methods 0.000 abstract 2
- 206010018910 Haemolysis Diseases 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 230000008588 hemolysis Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000003761 preservation solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
resumo método para obter uma suspensão estabilizada de glóbulos vermelhos e suspensão estabilizada a presente invenção refere-se a um método para obter uma suspensão estabilizada de glóbulos vermelhos que encapsulam um ingrediente ativo, a partir de rbcs resselados que incorporam o ingrediente ativo, sendo que o método compreende a incubação dos rbcs resselados em uma solução de incubação em uma osmolalidade não menor que 280 mosmol/kg, durante um período de tempo de 30 minutos ou mais, a solução de incubação é uma solução que não contém um agente que é desnaturante para a membrana de rbc, o meio líquido é, então, removido da suspensão incubada e os rbcs obtidos são colocados em suspensão em uma solução que permite a injeção da suspensão em um paciente. as suspensões obtidas são particularmente caracterizadas por um nível de hemoglobina extracelular mantido em 0,5 ou menor, em particular 0,2 g/dl ou menor e/ou uma taxa de hemólise mantida em 2 ou menos, em particular 1 % ou menos, em 72 h após colocação em suspensão em uma solução de conservação e a uma temperatura entre 2 e 8 °c.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1354204A FR3005420B1 (fr) | 2013-05-07 | 2013-05-07 | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| PCT/EP2014/059327 WO2014180897A1 (en) | 2013-05-07 | 2014-05-07 | Method for stabilising suspensions of red blood cells encapsulating an active ingredient, the suspensions obtained |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015028054A2 true BR112015028054A2 (pt) | 2017-07-25 |
Family
ID=49378358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015028054A BR112015028054A2 (pt) | 2013-05-07 | 2014-05-07 | método para obter uma suspensão estabilizada de glóbulos vermelhos e suspensão estabilizada |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10286008B2 (pt) |
| EP (1) | EP2994116B1 (pt) |
| JP (1) | JP6625970B2 (pt) |
| KR (1) | KR102013731B1 (pt) |
| CN (1) | CN105246467B (pt) |
| AU (1) | AU2014264650B2 (pt) |
| BR (1) | BR112015028054A2 (pt) |
| CA (1) | CA2910975C (pt) |
| CL (1) | CL2015003273A1 (pt) |
| ES (1) | ES2729343T3 (pt) |
| FR (1) | FR3005420B1 (pt) |
| HK (1) | HK1218714A1 (pt) |
| IL (1) | IL242468B (pt) |
| JO (1) | JO3549B1 (pt) |
| MX (1) | MX362839B (pt) |
| RU (1) | RU2668688C2 (pt) |
| SG (1) | SG11201509062RA (pt) |
| TR (1) | TR201908017T4 (pt) |
| WO (1) | WO2014180897A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| CA2944492A1 (en) | 2014-04-01 | 2015-10-08 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| EP3187190A1 (en) | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| SG11201805253SA (en) | 2016-01-11 | 2018-07-30 | Rubius Therapeutics Inc | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| HUE057901T2 (hu) | 2016-08-08 | 2022-06-28 | Aerase Inc | Összetételek és módszerek rák kezelésére argininkiürítéssel és immunonkológiai szerekkel |
| WO2019042628A1 (en) | 2017-08-31 | 2019-03-07 | Erytech Pharma | ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY |
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| JP2021505620A (ja) | 2017-12-05 | 2021-02-18 | イーレイズ・インコーポレーテッド | アルギナーゼ１欠損症を治療するための方法及び組成物 |
| JP7257182B2 (ja) * | 2019-02-27 | 2023-04-13 | 京セラ株式会社 | 検査装置および検査方法 |
| EP4147730A1 (en) * | 2021-09-09 | 2023-03-15 | ETH Zurich | Method of preparing a functional hydrogel material that can be injected |
| WO2023067200A1 (en) | 2021-10-24 | 2023-04-27 | Erytech Pharma | Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2655801C2 (de) * | 1976-12-09 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension |
| DE2740053A1 (de) | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
| US4389209A (en) * | 1980-06-18 | 1983-06-21 | The United States Of America As Represented By The Secretary Of Agriculture | Method of providing systemic protection from bloodsucking insects and other parasites using encapsulated additives in resealed erythrocytes |
| US4327710A (en) | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
| FR2529463B1 (fr) | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
| US4478824A (en) | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
| US4801777A (en) | 1987-09-03 | 1989-01-31 | Vanderbilt University | Blood rewarming method and apparatus |
| FR2660864A1 (fr) * | 1990-04-13 | 1991-10-18 | Guerbet Sa | Composition de contraste, procede de preparation de cette composition et application a l'imagerie. |
| FR2678512B1 (fr) | 1991-07-03 | 1995-06-30 | Novacell | Machine a internaliser. |
| AU680890B2 (en) | 1993-03-23 | 1997-08-14 | Cbr Laboratories, Inc. | Method and apparatus for encapsulation of biologically-active substances in cells |
| WO1995027203A1 (en) | 1994-04-05 | 1995-10-12 | Northern General Hospital N.H.S. Trust | Preparation and stabilisation of cell suspensions |
| DE69732225T2 (de) | 1997-05-05 | 2005-06-23 | Dideco S.R.L., Mirandola | Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür |
| WO2002010177A1 (en) | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
| RU2271540C2 (ru) * | 2003-07-21 | 2006-03-10 | Ставропольский научно-иследовательский противочумный институт | Способ получения биомагноиммуносорбента для обнаружения бактериальных антигенов (варианты) |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| FR2884717B1 (fr) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
| EP3225233B1 (en) | 2005-11-01 | 2019-08-14 | Wyeth LLC | Sodium chloride solution for drug reconstitution |
| FR2928270B1 (fr) * | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| FR2938332B1 (fr) | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
-
2013
- 2013-05-07 FR FR1354204A patent/FR3005420B1/fr active Active
-
2014
- 2014-05-05 JO JOP/2014/0156A patent/JO3549B1/ar active
- 2014-05-07 WO PCT/EP2014/059327 patent/WO2014180897A1/en active Application Filing
- 2014-05-07 JP JP2016512361A patent/JP6625970B2/ja active Active
- 2014-05-07 MX MX2015015374A patent/MX362839B/es active IP Right Grant
- 2014-05-07 ES ES14726095T patent/ES2729343T3/es active Active
- 2014-05-07 AU AU2014264650A patent/AU2014264650B2/en active Active
- 2014-05-07 TR TR2019/08017T patent/TR201908017T4/tr unknown
- 2014-05-07 RU RU2015152127A patent/RU2668688C2/ru active
- 2014-05-07 EP EP14726095.4A patent/EP2994116B1/en active Active
- 2014-05-07 SG SG11201509062RA patent/SG11201509062RA/en unknown
- 2014-05-07 KR KR1020157034227A patent/KR102013731B1/ko active IP Right Grant
- 2014-05-07 CA CA2910975A patent/CA2910975C/en active Active
- 2014-05-07 BR BR112015028054A patent/BR112015028054A2/pt not_active Application Discontinuation
- 2014-05-07 US US14/889,083 patent/US10286008B2/en active Active
- 2014-05-07 CN CN201480025939.1A patent/CN105246467B/zh active Active
-
2015
- 2015-11-05 IL IL242468A patent/IL242468B/en active IP Right Grant
- 2015-11-06 CL CL2015003273A patent/CL2015003273A1/es unknown
-
2016
- 2016-06-12 HK HK16106710.8A patent/HK1218714A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2910975A1 (en) | 2014-11-13 |
| MX2015015374A (es) | 2016-06-02 |
| WO2014180897A1 (en) | 2014-11-13 |
| EP2994116A1 (en) | 2016-03-16 |
| EP2994116B1 (en) | 2019-03-06 |
| FR3005420B1 (fr) | 2015-09-18 |
| FR3005420A1 (fr) | 2014-11-14 |
| US20160095884A1 (en) | 2016-04-07 |
| CN105246467B (zh) | 2018-11-27 |
| RU2668688C2 (ru) | 2018-10-02 |
| RU2015152127A (ru) | 2017-06-13 |
| RU2015152127A3 (pt) | 2018-03-30 |
| MX362839B (es) | 2019-02-19 |
| CL2015003273A1 (es) | 2016-05-27 |
| KR102013731B1 (ko) | 2019-08-23 |
| AU2014264650A1 (en) | 2015-11-19 |
| CA2910975C (en) | 2020-01-21 |
| CN105246467A (zh) | 2016-01-13 |
| JO3549B1 (ar) | 2020-07-05 |
| JP6625970B2 (ja) | 2019-12-25 |
| JP2016517899A (ja) | 2016-06-20 |
| AU2014264650B2 (en) | 2018-10-18 |
| KR20160005077A (ko) | 2016-01-13 |
| SG11201509062RA (en) | 2015-12-30 |
| TR201908017T4 (tr) | 2019-06-21 |
| HK1218714A1 (zh) | 2017-03-10 |
| IL242468B (en) | 2020-03-31 |
| US10286008B2 (en) | 2019-05-14 |
| ES2729343T3 (es) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028054A2 (pt) | método para obter uma suspensão estabilizada de glóbulos vermelhos e suspensão estabilizada | |
| BR112015017405A2 (pt) | composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas | |
| EA201890641A2 (ru) | СТИМУЛЯТОРЫ sGC | |
| BR112015021189A2 (pt) | métodos de banco de células de alta densidade | |
| BR112014015342A2 (pt) | células-tronco pluripotentes induzidas de células derivadas do tecido do cordão umbilical humano | |
| BR112014012306A2 (pt) | soluções de colina estabilizadas e métodos para preparar as mesmas | |
| BR112012028711A2 (pt) | métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit | |
| MX2020006720A (es) | Beta-caseina a2 y niveles de glucosa en sangre. | |
| ZA202210899B (en) | Solutons for increasing the stability and shelf life of an organ and tissue preservation solution | |
| EA201490795A1 (ru) | 3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции | |
| BR112012017994A2 (pt) | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio | |
| PE20151426A1 (es) | Solucion para preservar conductos vasculares | |
| BR112012032385A2 (pt) | método e aparelho de banho de pressão de névoa de gás de dióxido de carbono | |
| BR112015012308A2 (pt) | método de preservação de eritrócito | |
| Mei et al. | Investigation on the detrimental effects of salt stress on photosynthesis of Spirulina platensis | |
| AU2014101423A4 (en) | Abalone blood flavoured ethyl alcohol. | |
| UA125846U (uk) | Спосіб ліофілізації лейкоконцентрату кордової крові людини | |
| UA74165U (ru) | Способ подготовки ядросодержащих клеток пуповинной/ плацентарной крови к криоконсервированию | |
| RU2013101398A (ru) | Способ создания экспериментальной модели острого панкреатита у животного | |
| Fasulkov | INVESTIGATION OF SOME BIOCHEMICAL PARAMETERS IN BULGARIAN LOCAL GOATS DURING THE POSTPARTUM PERIOD | |
| Bidkhori et al. | HYPOXIA-MIMICKING AGENTS PROMOTE CXCR4 GENE EXPRESSION AND MIGRATION OF MESENCHYMAL STEM CELLS TOWARDS SDF1 | |
| Mozgovoy | Russian culture in Ukrainian linguistic context: policy and reality | |
| Wagner et al. | Plasma protein induced clustering of red blood cells in micro capillaries | |
| Ryabinin | Problems and prospects of creation of extracorporal systems for support of functional livers status | |
| Zelenyj | Acute toxicity of hydrocortisone acetate to Daphnia magna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |